[1]罗云良.沙美特罗替卡松联合复方异丙托溴铵治疗慢阻肺急性加重期的临床疗效及对肺功能的影响[J].医学信息,2023,36(21):130-133.[doi:10.3969/j.issn.1006-1959.2023.21.030]
　LUO Yun-liang.Effect of Salmeterol Xinafoate and Fluticasone Propionate Combined with Ipratropine Bromide and Salbutamol in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and its Effect on Lung Function[J].Journal of Medical Information,2023,36(21):130-133.[doi:10.3969/j.issn.1006-1959.2023.21.030]
点击复制

沙美特罗替卡松联合复方异丙托溴铵治疗慢阻肺急性加重期的临床疗效及对肺功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年21期
页码:
130-133
栏目:
药物与临床
出版日期:
2023-11-01

文章信息/Info

Title:
Effect of Salmeterol Xinafoate and Fluticasone Propionate Combined with Ipratropine Bromide and Salbutamol in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and its Effect on Lung Function
文章编号:
1006-1959（2023）21-0130-04
作者:
罗云良
（芦溪县人民医院急诊科，江西 芦溪 337200）
Author(s):
LUO Yun-liang
(Emergency Department of Luxi County People’s Hospital,Luxi 337200,Jiangxi,China)
关键词:
沙美特罗替卡松; 复方异丙托溴铵; 慢阻肺; 急性加重期; 肺功能
Keywords:
Salmeterol xinafoate and fluticasone propionate; Ipratropine bromide and salbutamol; Chronic obstructive pulmonary disease; Acute exacerbation; Lung function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2023.21.030
文献标志码:
A
摘要:
目的 评估沙美特罗替卡松联合复方异丙托溴铵治疗慢阻肺急性加重期临床疗效及对肺功能的影响。方法 选取2022年7月-2023年1月我院接诊的66例慢阻肺急性加重期患者为研究对象，采用随机数字表法分为观察组和对照组，各组33例。对照组采用常规+复方异丙托溴铵治疗，观察组在对照组基础上+沙美特罗替卡松吸入气雾剂治疗，比较两组临床疗效、肺功能指标、血清炎症因子水平以及临床不良反应发生情况。结果 观察组总有效率为96.97%，高于对照组的78.79%（P＜0.05）；两组治疗后患者用力肺活量（FVC）、第1秒用力呼气容积（FEV1）、FEV1/FVC水平均高于治疗前，且观察组高于对照组（P＜0.05）；两组治疗后患者白细胞介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）水平均低于治疗前，且观察组低于对照组（P＜0.05）；观察组不良反应发生率为9.09%，与对照组的15.15%比较，差异无统计学意义（P＞0.05）。结论 沙美特罗替卡松吸入气雾剂联合复方异丙托溴铵治疗慢阻肺急性加重期患者具有良好的临床疗效，可有效改善肺功能，降低血清炎症因子水平，且安全性相对较高。
Abstract:
Objective To evaluate the clinical efficacy of salmeterol xinafoate and fluticasone propionate combined with ipratropine bromide and salbutamol in the treatment of acute exacerbation of chronic obstructive pulmonary disease and its effect on lung function.Methods A total of 66 patients with acute exacerbation of chronic obstructive pulmonary disease who were admitted to our hospital from July 2022 to January 2023 were selected as the research objects. They were divided into observation group and control group by random number table method, with 33 patients in each group. The control group was treated with conventional therapy+ ipratropine bromide and salbutamol. The observation group was treated with salmeterol xinafoate and fluticasone propionate powder for inhalation on the basis of the control group. The clinical efficacy, lung function index, serum inflammatory factor level and clinical adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 96.97%, which was higher than 78.79% of the control group (P<0.05). After treatment, the levels of forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and FEV1/FVC in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). After treatment, the levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) in the two groups were lower than those before treatment, and those in the observation group were lower than the control group (P<0.05). The incidence of adverse reactions in the observation group was 9.09%, which was compared with 15.15% in the control group, the difference was not statistically significant (P>0.05).Conclusion Salmeterol xinafoate and fluticasone propionate powder for inhalation combined with ipratropine bromide and salbutamol has good clinical efficacy in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease, which can effectively improve lung function and reduce the level of serum inflammatory factors, with relatively high safety.

参考文献/References:

[1]邢丽莉,申力.低分子肝素钙、沙美特罗替卡松气雾剂(吸入)联合治疗急性加重期COPD的效果分析[J].中国继续医学教育,2018,10(15):126-127.[2]何恺韵,陈一明.吸入噻托溴铵与沙美特罗丙酸氟替卡松治疗慢阻肺患者的研究[J].黑龙江医药,2018,15(2):146-150.[3]刘佳铭,孙晓容,马千里，等.慢性阻塞性肺疾病患者三种生活质量问卷评估的倾向性调查[J].中华肺部疾病杂志(电子版),2020,13(6):808-810.[4]国家卫生健康委员会急诊医学质控中心,中华医学会急诊医学分会,中国医师协会急诊医师分会,等.中国慢性阻塞性肺疾病急性加重中西医诊治专家共识(2021)[J].中华危重病急救医学,2021,33(11):1281-1290.[5]章春花.布地奈德联合异丙托溴铵雾化吸入治疗慢阻肺急性加重期疗效分析[J].医学理论与实践,2017,30(21):3185-3186.[6]董健,张振建,金志强.沙美特罗替卡松粉吸入剂联合无创呼吸机治疗COPD并发呼吸衰竭的临床效果分析[J].解放军医药杂志,2018,30(9):84-88.[7]中华医学会.慢性阻塞性肺疾病基层诊疗指南(2018年)[J].中华全科医师杂志,2018,17(11):856-870.[8]韩飞,胡晨阳.布地奈德福莫特罗粉吸入剂联合复方异丙托溴铵溶液雾化在慢阻肺急性加重期治疗中的效果[J].现代诊断与治疗,2021,32(11):1711-1712.[9]马义铭,龙颖姣,陈燕.从2021年“罗马提议”看慢性阻塞性肺疾病急性加重定义及分级的变迁[J].结核与肺部疾病杂志,2022,3(1):1-3.[10]盖红梅,包红,但淑杰.噻托溴铵粉吸入剂联合呼吸训练对稳定期慢性阻塞性肺疾病的疗效观察[J].山西医药杂志,2018,47(24):2910-2913.[11]郁震,曹娟,王红梅,等.噻托溴铵联合沙美特罗替卡松对慢阻肺急性加重期患者免疫功能的影响[J].临床肺科杂志,2017,21(5):795-798.[12]张秀丽,陈涵,程绩,等.长效抗胆碱药联合β2-受体激动剂治疗慢性阻塞性肺疾病急性加重期患者的临床观察[J].检验医学与临床,2018,15(5):708-711.[13]张军战.异丙托溴铵联合布地奈德及沙丁胺醇治疗慢性阻塞性肺疾病急性加重期的临床疗效及安全性[J].实用临床医药杂志,2019,23(3):57-59.[14]黄霞,周彪,龙虎.噻托溴铵与无创正压通气对老年COPD合并呼吸衰竭患者血气分析,炎症因子及APN、SOD、PAB水平的影响[J].国际呼吸杂志,2019,39(5):345-349.[15]聂言臣,张特,王宗立.无创呼吸机联合沙美特罗替卡松粉剂吸入治疗慢性阻塞性肺疾病急性加重并发呼吸衰竭的疗效及对患者预后生存质量的影响[J].中国药物与临床,2019,19(8):1229-1231.[16]韦永刚,付德安.噻托溴铵吸入剂与沙美特罗替卡松粉吸入剂联合治疗对中重度慢性阻塞性肺疾病稳定期患者肺功能和生活质量的影响[J].新乡医学院学报,2018,35(8):739-742.[17]张永辉.噻托溴铵与沙美特罗替卡松联用雾化吸入对COPD患者急性加重期的疗效及其对肺功能及炎症因子水平的影响[J].抗感染药学,2019,16(4):693-696.[18]何国庆,秦勤,罗兰.慢性阻塞性肺疾病急性加重期患者治疗前后肺功能、SIRS评分及血清炎症因子水平变化与预后的相关性研究[J].心肺血管病杂志,2018,37(8):757-760.[19]李成博,刘璐,海鑫.糖皮质激素联合复方异丙托溴胺治疗慢性阻塞性肺疾病急性加重期的效果及对血清炎性因子水平的影响[J].四川医学,2018,39(3):316-319.[20]王娟,马菁菁.复方异丙托溴铵雾化吸入联合百令胶囊治疗AECOPD患者的效果及机制[J].中南医学科学杂志,2019,47(5):465-468.

相似文献/References:

[1]温 蕾.复方异丙托溴铵常温雾化与加温雾化治疗 慢阻肺的护理效果分析[J].医学信息,2018,31(06):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]
　WEN Lei.Analysis of Nursing Effect of Compound Ipratropium Bromide Nebulization at Room Temperature and Heating Atomization in Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(21):170.[doi:10.3969/j.issn.1006-1959.2018.06.061]

更新日期/Last Update: 1900-01-01